Neutrophils as potential therapeutic targets for breast cancer. 2023

Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China.

Breast cancer (BC) remains the foremost cause of cancer mortality globally, with neutrophils playing a critical role in its pathogenesis. As an essential tumor microenvironment (TME) component, neutrophils are emerging as pivotal factors in BC progression. Growing evidence has proved that neutrophils play a Janus- role in BC by polarizing into the anti-tumor (N1) or pro-tumor (N2) phenotype. Clinical trials are evaluating neutrophil-targeted therapies, including Reparixin (NCT02370238) and Tigatuzumab (NCT01307891); however, their clinical efficacy remains suboptimal. This review summarizes the evidence regarding the close relationship between neutrophils and BC, emphasizing the critical roles of neutrophils in regulating metabolic and immune pathways. Additionally, we summarize the existing therapeutic approaches that target neutrophils, highlighting the challenges, and affirming the rationale for continuing to explore neutrophils as a viable therapeutic target in BC management.

UI MeSH Term Description Entries
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments

Related Publications

Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
June 2006, Discovery medicine,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
January 2022, Frontiers in oncology,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
April 2022, Nature reviews. Gastroenterology & hepatology,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
April 2020, Biochimica et biophysica acta. Gene regulatory mechanisms,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
January 2013, Frontiers in cellular and infection microbiology,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
April 2020, Nature reviews. Drug discovery,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
February 2024, Immunology,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
June 2020, Expert opinion on therapeutic targets,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
January 2022, Chinese medical journal,
Yi-Ting Gong, and Li-Jun Zhang, and Yi-Chen Liu, and Min Tang, and Jia-Yi Lin, and Xin-Yi Chen, and Yi-Xu Chen, and Yue Yan, and Wei-Dong Zhang, and Jin-Mei Jin, and Xin Luan
January 2022, Frontiers in oncology,
Copied contents to your clipboard!